Frontier Biotech Enters into Agreement with GSK for siRNA Therapies
Thursday, February 26, 2026
Frontier Biotechnologies has entered into a global exclusive licensing agreement with GSK covering therapeutic applications based on small interfering RNA (siRNA) technology.
siRNA-based therapies have gained increasing attention in recent years. This approach enables targeted gene silencing and may address disease targets that have been difficult to treat using traditional drug development methods. The platform has shown potential for durable and specific treatment effects across a broad range of conditions. Development efforts are expanding beyond rare diseases to include more common chronic conditions, such as cardiovascular, cerebrovascular and metabolic disorders, indicating wider market opportunity.
Under the terms of the agreement, GSK will obtain worldwide exclusive rights to develop, manufacture and commercialise two siRNA candidates from Frontier Biotech’s pipeline. One candidate is currently in the Investigational New Drug (IND) approval stage, while the second remains at the preclinical stage.
The deal highlights Frontier Biotech’s capabilities in early-stage research and development of siRNA medicines and marks a significant step in advancing its international strategy.
Frontier Biotech will receive an upfront payment of US$40 million. The agreement also includes up to US$963 million in potential milestone payments linked to development, regulatory approval and commercial progress across both programmes. In addition, Frontier Biotech will be entitled to tiered royalties based on worldwide net sales.
The company will oversee early development activities for the two investigational candidates. One product is progressing through a Phase I clinical trial in China, while the other is completing the IND process. GSK will take responsibility for all subsequent global clinical development, regulatory submissions and commercialisation activities.
The agreement also supports GSK’s strategic focus on immunology and inflammation-related diseases, including kidney disorders, and further strengthens its pipeline in oligonucleotide-based therapies.
Source: prnewswire.com
